Personalizing the Path in mCRPC: Optimizing Chemotherapy and Aggressive Variant Prostate Cancer (AVPC) - Episode 4

Recognizing and Treating AVPC

,

A panel of experts discuss defining and recognizing aggressive variant prostate cancer (AVPC) and neuroendocrine prostate cancer (NEPC) through clinical and molecular features, first-line treatment selection comparing platinum-etoposide versus taxane-platinum regimens, and individualized application of treatment guidelines based on disease characteristics and patient factors.

EP. 1: The Role of Chemotherapy in Today’s mCRPC Landscape
EP. 2: Overcoming Barriers to Cabazitaxel and Optimizing Sequencing
EP. 3: Individualizing Chemotherapy: Dosing, Tolerability, and Treatment Duration
Now Viewing
EP. 4: Recognizing and Treating AVPC
EP. 5: Integrating Immunotherapy – Lessons from Small Cell Lung Cancer
EP. 6: Balancing Intensity, Duration, and Maintenance in Treatment
EP. 7: Biomarkers, Disease Tracking, and Tumor Evolution

This segment focuses on recognizing aggressive variant prostate cancer (AVPC) and neuroendocrine prostate cancer (NEPC) using clinical features (rapid progression, visceral disease, low PSA) and molecular characteristics (loss of AR signaling, TP53/RB1 alterations). The panel compares first-line treatment approaches, including platinum–etoposide versus taxane–platinum regimens, noting the lack of definitive comparative data. Experts emphasize individualized application of guidelines, tailoring regimen selection to disease phenotype, prior therapies, performance status, and patient goals.